Comparison of the efficacy and safety of one inhalation of Symbicort Turbuhaler 160/4.5 mcg bid plus as-needed with two inhalations of SeretideTM EvohalerTM 25/125 mcg bid plus Terbutaline Turbuhaler 0.4 mg as-needed, and one inhalation of Symbicort Turbuhaler 320/9 mcg bid plus Terbutaline Turbuhaler 0.4 mg as-needed. A 6-month, randomised, double-blind, double-dummy, parallel-group, active-controlled, multicentre, phase IIIB study in adult and adolescent asthmatic patients.
Study identifier:SD-039-0735
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Comparison of the efficacy and safety of one inhalation of Symbicort Turbuhaler 160/4.5 mcg bid plus as-needed with two inhalations of SeretideTM EvohalerTM 25/125 mcg bid plus Terbutaline Turbuhaler 0.4 mg as-needed, and one inhalation of Symbicort Turbuhaler 320/9 mcg bid plus Terbutaline Turbuhaler 0.4 mg as-needed. A 6-month, randomised, double-blind, double-dummy, parallel-group, active-controlled, multicentre, phase IIIB study in adult and adolescent asthmatic patients.
Medical condition
asthma
Phase
N/A
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Dec 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
